BroveX PSE DM Tablets Drug Interactions
Currently displaying 86 drugs known to have a major interaction with BroveX PSE DM Tablets (brompheniramine / dextromethorphan / pseudoephedrine).
- 86 major drug interactions
- 456 moderate drug interactions
- 8 minor drug interactions
Major interactions with BroveX PSE DM Tablets (brompheniramine / dextromethorphan / pseudoephedrine)
Note: Showing generic names only.
- maprotiline
- mavorixafor
- meperidine
- methotrimeprazine
- methylene blue
- methylergonovine
- methysergide maleate
- milnacipran
- mirtazapine
- palonosetron
- paroxetine
- pentazocine
- phenelzine
- potassium chloride
- potassium citrate
- procarbazine
- propoxyphene
- protriptyline
BroveX PSE DM Tablets alcohol/food interactions
There are 2 alcohol/food interactions with BroveX PSE DM Tablets (brompheniramine / dextromethorphan / pseudoephedrine).
BroveX PSE DM Tablets disease interactions
There are 10 disease interactions with BroveX PSE DM Tablets (brompheniramine / dextromethorphan / pseudoephedrine) which include:
- cardiovascular disease
- anticholinergic effects
- asthma/COPD
- cardiovascular
- renal/liver disease
- GI narrowing
- PKU
- BPH
- diabetes
- glaucoma
More about BroveX PSE DM Tablets (brompheniramine / dextromethorphan / pseudoephedrine)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- Drug class: upper respiratory combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.